Recent clinical evidence on creatine as a depression treatment reveals three critical findings for patients and healthcare providers. First, preliminary research indicates that creatine supplementation may enhance response to standard antidepressant therapy, with two randomized trials demonstrating positive outcomes specifically in women with major depressive disorder. Second, this promising signal is tempered by the lack of benefit observed in three comparable trials, indicating that results are not yet consistent or generalizable.
Third, and most importantly, current evidence is insufficient to recommend creatine for routine psychiatric care. Before clinical guidelines can incorporate creatine as an evidence-based treatment option, larger, more rigorous studies are necessary to clarify efficacy, establish optimal protocols, and identify which patients are most likely to respond. Individuals interested in creatine supplementation should consult their healthcare provider before beginning treatment.
Read the full article on GMJ Newsroom.
Was this article helpful?
